Gauging risks for kidney failure or death in individuals was similar when using measured GFR (reference standard) or estimated GFR based on both filtration markers creatinine and cystatin C combined.
Provided by PR NewswireMay 27, 2026, 10:40:00 AM Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First ...
SHANGHAI, May 27, 2026 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that ...
NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients with relapsed EGFR exon 20 insertion–mutated NSCLC ...
Chinese Medical Journals Publishing House Co., Ltd. Numerous EGFR-TKIs are approved for EGFR-sensitive mutation NSCLC, including gefitinib, erlotinib, icotinib, osimertinib, and 11 others. First-line ...
EGFRmSig offers a centroid-based method to predict an EGFR mutation signature (mSig) from gene expression data in lung adenocarcinoma (LUAD). The package implements predefined EGFR wild-type (WT) and ...
The FDA accepted Summit Therapeutics' application for ivonescimab with chemotherapy for EGFR-mutated non-small cell lung cancer post-tyrosine kinase inhibitor therapy. The application is supported by ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort. The study reported a median duration of response of 8.7 months and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results